Heart failure (HF) is a major cause of hospital admissions in the US, with over 6 million hospital days annually. More than 40% of hospitalized patients with HF have diabetes mellitus (DM), which increases the risk of recurrent hospitalizations for HF with reduced and preserved ejection fraction by more than two-fold. Current methods for assessing glycemic control do not consider fluctuations in blood glucose levels, known as glycemic variability. High glycemic variability is a poor prognostic marker for HF re-hospitalizations. Given the significant prevalence and impact of DM in individuals with HF, it is crucial to examine whether improving glycemic control and avoiding hypoglycemia could lead to a decrease in HF readmissions. Real-time continuous glucose monitoring (rt-CGM), which provides glucose measurements as frequently as every 5 minutes, has improved glycemic control in insulin-treated adults with DM compared to the standard of care, capillary point-of-care blood glucose testing (POC). Researchers will monitor participants during their hospital stay and 3 months after discharge.
Age range
18 Years – 90 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Mean Daily BG concentration after discharge (DC)
Timeframe: After hospital discharge up to 12 weeks
Frequency of clinically significant hypoglycemia after discharge
Timeframe: After hospital discharge up to 12 weeks
Frequency of overall and nocturnal hypoglycemia events after discharge
Timeframe: After hospital discharge up to 12 weeks
Percentage of glucose readings and time within target of 70 - 180 mg/dl
Timeframe: After hospital discharge up to 12 weeks
Percentage of time within target of 70 - 180 mg/dl
Timeframe: After hospital discharge up to 12 weeks
Frequency of hyperglycemia > 180 mg/dl and >250 mg/dl
Timeframe: After hospital discharge up to 12 weeks
Percent of time with hyperglycemia
Timeframe: After hospital discharge up to 12 weeks
Glycemic variability
Timeframe: After hospital discharge up to 12 weeks